Format

Send to

Choose Destination
Intern Med J. 2014 Dec;44(12b):1350-63. doi: 10.1111/imj.12599.

Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014.

Author information

1
Department of Microbiology and Infectious Diseases, Royal Hobart Hospital, Hobart, Tasmania.

Erratum in

  • Intern Med J. 2014 Apr;45(4):469. Dosage error in article text.

Abstract

Pneumocystis jirovecii infection (PJP) is a common cause of pneumonia in patients with cancer-related immunosuppression. There are well-defined patients who are at risk of PJP due to the status of their underlying malignancy, treatment-related immunosuppression and/or concomitant use of corticosteroids. Prophylaxis is highly effective and should be given to all patients at moderate to high risk of PJP. Trimethoprim-sulfamethoxazole is the drug of choice for prophylaxis and treatment, although several alternative agents are available.

KEYWORDS:

Pneumocystis carinii; Pneumocystis jirovecii; haematological malignancy; prophylaxis; solid-organ tumour; treatment

PMID:
25482745
DOI:
10.1111/imj.12599
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center